BMSCs from CML patients showed increased efficiency to accelerate CML cell proliferation, enhance the drug resistance of K562 cells and up-regulate the expression of FZD7. The gene discussed is FZD7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.